Alto Neuroscience, Inc. Financing Cash Flow
Alto Neuroscience, Inc. (ANRO) reported Financing Cash Flow of $114.67 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-12
- Alto Neuroscience, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was -$273.00K, a 144.54% decline year-over-year.
- Alto Neuroscience, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $114.94M, a 1159.35% increase year-over-year.
- Alto Neuroscience, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $50.19M, a 102318.37% increase year-over-year.
- Alto Neuroscience, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $153.00K, a 88.38% decline year-over-year.
- Alto Neuroscience, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $60.08M, a 55.72% decline from fiscal 2024.
- Alto Neuroscience, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $135.69M, a 99.16% increase from fiscal 2023.
- Alto Neuroscience, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $68.13M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$273.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $114.67M 10-Q · filed 2026-08-12 | $164.85M derived: sum of 3 quarters · filed 2026-08-12 | $165.01M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $114.94M 10-Q · filed 2026-05-13 | $165.13M derived: sum of 2 quarters · filed 2026-05-13 | $165.28M derived: sum of 3 quarters · filed 2026-05-13 | $165.89M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $50.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $50.34M derived: sum of 2 quarters · filed 2026-03-16 | $50.95M derived: sum of 3 quarters · filed 2026-08-12 | $60.08M 10-K · filed 2026-03-16 |
| 2025-09-30 | $153.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $766.00K derived: sum of 2 quarters · filed 2026-08-12 | $9.89M 10-Q · filed 2025-11-12 | $9.94M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $613.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $9.74M 10-Q · filed 2026-08-12 | $9.79M derived: sum of 3 quarters · filed 2026-08-12 | $11.11M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $9.13M 10-Q · filed 2026-05-13 | $9.18M derived: sum of 2 quarters · filed 2026-05-13 | $10.49M derived: sum of 3 quarters · filed 2026-05-13 | $10.26M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $49.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $1.37M derived: sum of 2 quarters · filed 2026-03-16 | $1.13M derived: sum of 3 quarters · filed 2026-03-16 | $135.69M 10-K · filed 2026-03-16 |
| 2024-09-30 | $1.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.08M derived: sum of 2 quarters · filed 2025-11-12 | $135.64M 10-Q · filed 2025-11-12 | $178.77M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$234.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $134.32M 10-Q · filed 2025-08-13 | $177.46M derived: sum of 3 quarters · filed 2025-08-13 | $177.51M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $134.56M 10-Q · filed 2025-05-14 | $177.69M derived: sum of 2 quarters · filed 2025-05-14 | $177.74M derived: sum of 3 quarters · filed 2025-05-14 | $177.69M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $43.13M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $43.18M derived: sum of 2 quarters · filed 2025-03-20 | $43.13M derived: sum of 3 quarters · filed 2025-03-20 | $68.13M 10-K · filed 2025-03-20 |
| 2023-09-30 | $49.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$2.00K derived: sum of 2 quarters · filed 2024-11-12 | $25.00M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | -$51.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $24.95M 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $25.00M 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |